DaVita Labs appoints vp and general manager

Chronic kidney disease laboratory hires Leslie Mirani

DaVita Labs, a specialist laboratory focused on chronic kidney disease, has appointed Leslie Mirani as vice president and general manager.

Mirani brings to DaVita Labs more than 25 years’ experience in commercial sales and marketing – primarily renal-focused – in the pharmaceutical industry. She previously worked for Human Genome Sciences as an immunology sales director and as vice president for Amgen’s nephrology business unit for 18 years.

DaVita Labs has 86,700ft2 dedicated to its clinical diagnostic laboratories between its two locations in Fort Lauderdale and DeLand, Florida, US.

You may also like

Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

RHEOFREED: A game-changing innovation in lyophilization technology

Dec Group announces its partnership with Kobelco Eco Solutions, Japan, and presents RHEOFREED®, a revolutionary mixer-type freeze dryer at CPHI Frankfurt 2025
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Manufacturing

Merck breaks ground on $3bn US manufacturing centre

The 400,000 sqft Elkton expansion forms part of Merck’s $70bn US investment plan to bolster domestic pharmaceutical manufacturing and R&D, creating more than 500 new full-time roles
Research & Development

AlzeCure Pharma publishes response letter clarifying Alzstatin’s distinct mechanism in Alzheimer’s treatment

AlzeCure Pharma and leading academic collaborators have published a response in JPET addressing recent commentary on Alzstatin’s γ-secretase modulation data, reaffirming the promise of lead candidate ACD680 in Alzheimer’s therapy
Regulatory

NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case

The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach
Subscribe now